New Therapeutic Options in the Medical Management of Advanced Melanoma

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 4, 2010, Pages 249-257

  Lutzky, Jose ^a  

^a Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIIDIOTYPIC ANTIBODY; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYTOKINE; DACARBAZINE; GANGLIOSIDE; GLYCOPROTEIN GP 100; HISTAMINE; INTERLEUKIN 2; IPILIMUMAB; LOMEGUATRIB; NITROSOUREA; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PLX 4032; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SELUMETINIB; SORAFENIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TICILIMUMAB; TUMOR VACCINE; UNINDEXED DRUG; VELIMOGENE ALIPLASMID; VINBLASTINE; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DIARRHEA; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MELANOMA; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 79251514285     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.10.006     Document Type: Review

References (121)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
3. Verma S., Quirt I., McCready D., et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006, 106:1431-1442.
4. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
5. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
6. Phan G.Q., Attia P., Steinberg S.M., et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19:3477-3482.
7. Atkins M.B., Mier J.W., Parkinson D.R., et al. Hypothyroidism after treatment with IL-2 and LAK cells. N Engl J Med 1988, 318:1557-1563.
8. Sullivan R.J., Hoshida Y., Brunet J., et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response [abstract 9003]. J Clin Oncol 2009, 27(suppl):15s.
9. Sabatino M., Kim-Schulze S., Panelli M.C., et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009, 27:2645-2652.
10. Sparano J.A., Fisher R.I., Sunderland M., et al. Randomized phase II trial of treatment with high-dose IL-2 either alone or in combination with interferon alpha 2a in patients with advanced melanoma. J Clin Oncol 1993, 11:1969-1977.
11. Lutzky J., Lawson D.H., Enriquez-Nunez Y., et al. Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma. J Clin Oncol 2010, 28(suppl):15s. [abstract 8560].
12. Agarwala S.S., Glaspy J., O'Day S.J., et al. Results from a randomized phase III study comparing combined treatment with histamine hydrochloride plus IL-2 versus IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2002, 20:125-133.
13. Chapman P.B. Combining a peptide vaccine with high-dose interleukin-2. J Clin Oncol 2008, 26:2250-2251.
14. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21:233-240.
15. Schwartzentruber D.J., Lawson D., Richards J., et al. A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210 M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009, 27(suppl):18s. [abstract CRA 9011].
16. Falkson C.I., Ibrahim J., Kirkwood J.M., et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743-1751.
17. Middleton M.R., Lorigan P., Owen J., et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000, 82:1158-1162.
18. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
19. Richards J.M., Gale D., Mehta N., et al. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin Oncol 1999, 17:651-657.
20. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999, 17:968-975.
21. Keilholz U., Punt C.J., Gore M., et al. Dacarbazine, cisplatin, and interferon-alpha-2 with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005, 23:6747-6755.
22. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma E3695: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26:5748-5754.
23. O'Day S.J., Atkins M.B., Boasberg P., et al. Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009, 27:6207-6212.
24. Dudley M.E., Rosenberg S.A. Adoptive cell transfer therapy [review]. Semin Oncol 2007, 34:524-531.
25. + T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703.
26. Chapman P.B. Melanoma vaccines. Semin Oncol 2007, 34:516-523.
27. Morton D.L. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007, 25(suppl):474s. [abstract 8508].
28. Eggermont A.M. Immunotherapy: vaccine trials in melanoma-time for reflection. in Nat Rev Clin Oncol 2009, 6:256-258.
29. Eggermont A.M., Suciu S., Rutkowski P., et al. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. J Clin Oncol 2010, 28(suppl):15s. [abstract 8505].
30. Soares H.P., Lutzky J. Velimogene aliplasmid. Expert Opin Biol Ther 2010, 10:841-851.
31. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27:5763-5771.
32. Good L.M., Miller M.D., High W.A. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol Mar 22, 2010, [Epub ahead of print].
33. Oratz R., Hauschild A., Sebastian G., et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003, 13:59-66.
34. Byrne C.M., Thompson J.F., Johnston H., et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005, 15:45-51.
35. Von Wussow P., Block B., Hartmann F., et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988, 61:1071-1074.
36. Radny P., Caroli U.M., Bauer J., et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620-1626.
37. Si Z., Hersey P., Coates A.S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996, 6:247-255.
38. Tan J.K., Ho V.C. Pooled analysis of the efficacy of Bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993, 19:985-990.
39. Steinmann A., Funk J.O., Schuler G., et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000, 43:555-556.
40. Thompson J.F., Hersey P., Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res 2008, 18:405-411.
41. Agarwala S.S., Thompson J.F., Smithers B.M. Chemoablation of metastatic melanoma with Rose bengal (PV-10). J Clin Oncol 2010, 28(suppl):15s. [abstract 8534].
42. Wolchok J.D., Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008, 13(suppl):2-9.
43. Ribas A., Bozon V.A., Lopez-Berestein G., et al. Phase I trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. J Clin Oncol 2005, 23(suppl):716s. [abstract 7524].
44. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008, 13:10-15.
45. Ribas A., Hauschild A., Kefford R., et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008, 26(suppl):15S. LBA1911.
46. O'Day S., Weber J., Lebbe C. Ipilimumab treatment may be associated with a long-term survival benefit: 18-month survival rate of patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009, 27(suppl):15s.
47. Wolchok J.D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
48. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
49. Lawrence D.P., Hamid O., McDermott D.F., et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol 2010, 28(suppl):15s. [abstract 8523].
50. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053.
51. Lutzky J., Wolchok J., Hamid O., et al. Association between immune-related adverse events and disease control or overall survival in patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009, 27(suppl):15s. [abstract 9034].
52. Saenger Y.M., Wolchok J.D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008, 17. 8-1.
53. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
54. Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00324155.
55. Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00636168.
56. Korman A., Chen B., Wang C., et al. Activity of anti-PD-1 in murine tumor models: role of 2host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4. J Immunol 2007, 178. 48-37.
57. Sznol M., Powderly J.L., Smith D.C., et al. Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010, 28(suppl):15s. [abstract 2506].
58. So T., Lee S.W., Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008, 19:253-262.
59. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
60. Bleehen N.M., Newlands E.S., Lee S.M., et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 13:910-913.
61. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166. [Published correction appears in J Clin Oncol 2000 18:2351].
62. Patel P.M., Suciu S., Mortier L., et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomised phase III study (EORTC 18032) [abstract LBA8]. Ann Oncol 2008, 19(suppl 8):3.
63. Agarwala S.S., Kirkwood J.M., Gore M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004, 22:2101-2107.
64. Margolin K., Atkins B., Thompson A., et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002, 128:214-218.
65. Jacquillat C., Khayat D., Banzet P., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66:1873-1878.
66. Yang A.S., Chapman P.B. The history and future of chemotherapy for melanoma. Hematol/Oncol Clin North Am 2009, 23:583-597.
67. Bajetta E., Del Vecchio M., Bernard-Marty C., et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002, 29:427-445.
68. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
69. Falkson C.I., Ibrahim J., Kirkwood J.M., et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743-1751.
70. Rusthoven J.J., Quirt I.C., Iscoe N.A., et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996, 14:2083-2090.
71. Hersh E.M., O'Day S.J., Ribas A., et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010, 116:155-163.
72. Boasberg P., Cruickshank S., Hamid O. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol 2009, 27(suppl):15s. [abstract 9061].
73. Perez D.G., Suman V.J., Fitch T.R., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study N047A. Cancer 2009, 115:119-127.
74. A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00864253.
75. Piro L.D. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncol Williston Park 2004, 18(suppl 10):5-10.
76. Busch C., Geisler J., Lillehaug J.R., et al. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 2010, 46:2127-2133.
77. Ranson M., Hersey P., Thompson D., et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007, 25:2540-2545.
78. Palma J.P., Rodriguez L.E., Bontcheva-Diaz V.D., et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008, 28:2625-2635.
79. Plummer R., Jones C., Middleton M., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923.
80. Penning T.D., Zhu G.D., Gandhi V.B., et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009, 52:514-523.
81. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
82. A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00804908.
83. Hainsworth J.D., Infante J.R., Spigel D.R., et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116:4122-4129.
84. Schicher N., Paulitschke V., Swoboda A., et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009, 15:3495-3502.
85. Guenterberg K.D., Grignol V.P., Relekar K.V., et al. A pilot study of bevacizumab and interferon-alpha2b in ocular melanoma. Am J Clin Oncol May 7, 2010, [Epub ahead of print].
86. Vihinen P.P., Hernberg M., Vuoristo M.S., et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010, 20:318-325.
87. Dummer R., Michielin O., Seifert B., et al. First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). J Clin Oncol 2010 2010, 28(suppl):15s. [abstract 8521].
88. Grignol V.P., Olencki T., Taylor C., et al. Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma. J Clin Oncol 2010 2010, 28(suppl):15s. [abstract 8520].
89. Fruehauf J.P., Lutzky J., McDermott D.F., et al. Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. J Clin Oncol 2008, 26(suppl):9006. [abstract 9006].
90. A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (BEAM) Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00434252.
91. Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00790010.
92. Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00301990.
93. Marneros A.G. Tumor angiogenesis in melanoma. Hematol/Oncol Clin North Am 2009, 23:431-446. vii-viii.
94. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15:7711-7718.
95. Flaherty K.T., Brose M., Schuchter L., et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 2004, 22(suppl):14.
96. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
97. McDermott D.F., Sosman J.A., Gonzalez R., et al. Doubleblind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008, 26:2178-2185.
98. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
99. Flaherty K.T., Lee S.J., Schuchter L.M., et al. Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma[abstract 8511]. J Clin Oncol 2010, 28(suppl):15s.
100. O'Day S., Gonzalez R., Lawson D., et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009, 27:5452-5458.
101. Vukovic V.M., Hauschild A., Eggermont A.M., et al. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update. J Clin Oncol 2010 2010, 28(suppl):15s. [abstract 8550].
102. Montagut C., Settleman J. Targeting the ref-MEK-ERK pathway in cancer therapy. Cancer Lett 2009, 283:125-134.
103. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
104. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
105. Hodi F.S., Friedlander P., Corless C.L., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051.
106. Lutzky J., Bauer J., Bastian B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigments Cell Melanoma Resour 2008, 21:492-493.
107. Carvajal R.D., Chapman P.B., Wolchok J.D., et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT [abstract 9001]. J Clin Oncol 2009, 27(suppl):15s.
108. A Study of AMNN107 Against Dacarbazine (DTIC) in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM) Accessed October 19, 2010. http://www.clinicaltrials.gov/ct2/show/NCT01028222.
109. Flaherty K.T., Puzanov I., Kim K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
110. Garber K. Cancer research. Melanoma drug vindicates targeted approach. Science 2009, 326:1619.
111. Flaherty K., Puzanov I., Sosman J., et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27(suppl):15s. [abstract 9000].
112. A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma http://www.clinicaltrials.gov/ct2/show/NCT01006980.
113. Sebolt-Leopold J.S. MEK inhibitors: a therapeutic approach to targeting the ras-MAP kinase pathway in tumors. Curr Pharm Des 2004, 10:1907-1914.
114. Friday B.B., Adjei A.A. Advances in targeting the ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008, 14:342-346.
115. Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients http://www.clinicaltrials.gov/ct2/show/NCT00936221.
116. Randomised Study to Compare the Efficacy of AZD6244 vs TMZ http://www.clinicaltrials.gov/ct2/show/NCT00338130.
117. Madhunapantula S.V., Robertson G.P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma [review]. Pigments Cell Melanoma Resour 2009, 22:400-419.
118. Palmieri G., Capone M., Ascierto M.L., et al. Main roads to melanoma [review]. J Transl Med 2009, 7:86.
119. Prickett T.D., Agrawal N.S., Wei X., et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127-1132.
120. Merchant A.A., Matsui W. Targeting hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010, 15:3130-3140.
121. Stecca B., Mas C., Clement, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the ras-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007, 104:5895-5900. V ZM.